| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192608 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(9 years from now) | |
| US9072781 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(9 years from now) | |
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(9 years from now) | |
Morphine Sulfate is owned by Fresenius Kabi Usa.
Morphine Sulfate contains Morphine Sulfate.
Morphine Sulfate has a total of 3 drug patents out of which 0 drug patents have expired.
Morphine Sulfate was authorised for market use on 30 October, 2013.
Morphine Sulfate is available in solution;intramuscular, intravenous dosage forms.
Morphine Sulfate can be used as treatment of pain.
The generics of Morphine Sulfate are possible to be released after 12 March, 2034.
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 30 October, 2013
Treatment: Treatment of pain
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS
More Information on Dosage
MORPHINE SULFATE family patents
